A tighter archive for life-science signals.
Search once, then narrow by source or topic.
A potential gene therapy for heart failure is an approach decades in the making
A potential gene therapy for heart failure is an approach decades in the making
Biopharma layoffs surged last year, but 2026 is a chance to turn the page
Biopharma layoffs surged last year, but 2026 is a chance to turn the page
Big Pharma shops Chinese biotechs to stock GLP-1 pipelines
Big Pharma shops Chinese biotechs to stock GLP-1 pipelines
US drug pricing policies are ‘red lights’ for investors, and China beckons
US drug pricing policies are ‘red lights’ for investors, and China beckons
Cancer R&D is thriving. Here are the areas to watch in 2026.
Cancer R&D is thriving. Here are the areas to watch in 2026.
Lilly, Takeda targeted by legal strategy usually reserved for the mob
Lilly, Takeda targeted by legal strategy usually reserved for the mob
Texas, N. Carolina, Ohio, Pennsylvania — where pharma manufacturing investments have surged
Texas, N. Carolina, Ohio, Pennsylvania — where pharma manufacturing investments have surged
Trump unveils healthcare affordability plan
Trump unveils healthcare affordability plan
The clinical candidates pharma execs are tracking
The clinical candidates pharma execs are tracking
It’s crunch time for US biopharma M&A. Can drugmakers strike deals despite persisting anxieties?
It’s crunch time for US biopharma M&A. Can drugmakers strike deals despite persisting anxieties?
Lilly, Novo test direct-to-employer approach that could cut out PBMs and lower costs
Lilly, Novo test direct-to-employer approach that could cut out PBMs and lower costs
3 positive trends for Massachusetts’ biopharma sector
3 positive trends for Massachusetts’ biopharma sector
A biotech’s snakebite pill is drawing the US military’s interest
A biotech’s snakebite pill is drawing the US military’s interest
What Sanofi’s multiple sclerosis troubles could mean for the space
What Sanofi’s multiple sclerosis troubles could mean for the space
PharmaVoice’s Crystal Ball: What’s next for AI and drug R&D
PharmaVoice’s Crystal Ball: What’s next for AI and drug R&D
The wellness industry is HHS’ new belle of the ball
The wellness industry is HHS’ new belle of the ball
Billionaire Sean Parker has already shaken up cancer R&D. Can his nonprofit fix the funding gap?
Billionaire Sean Parker has already shaken up cancer R&D. Can his nonprofit fix the funding gap?
C-suite priorities give a sneak peek into AI’s pharma future
C-suite priorities give a sneak peek into AI’s pharma future
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page